Glenmede Trust’s Denali Therapeutics DNLI Stock Holding History

Glenmede Trust’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-41	Closed	-$1K	–	1502
2020 Q3	$1K	Hold	41	–	–	﹤0.01%	2334
2020 Q2	$0	Buy	+41	New	+$964	﹤0.01%	2483

Other funds holding DNLI

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Glenmede Trust's DNLI Position: Q4 2020 in Review

Glenmede Trust sold out of Denali Therapeutics (DNLI) in Q4 2020, closing a stake of 41 shares — an estimated $1K sold.

Glenmede Trust first reported a position in DNLI in Q2 2020 and held it in 2 quarters. The position peaked at $1K in Q3 2020. 204 funds tracked by Wall St. Rank hold DNLI as of Q4 2020.

Glenmede Trust reported no remaining Denali Therapeutics position as of Q4 2020 after selling out during the quarter.
Glenmede Trust sold 41 Denali Therapeutics shares in Q4 2020, an estimated $1K.
Glenmede Trust first reported a position in Denali Therapeutics in Q2 2020 and held it in 2 quarters.
Glenmede Trust's Denali Therapeutics position peaked at $1K in Q3 2020.
204 funds tracked by Wall St. Rank held Denali Therapeutics as of Q4 2020.

Based on Glenmede Trust's 13F filing for Q4 2020, filed 16 Feb 2021.